Close

Janssen gets FDA approval for Tremfya One-Press patient-controlled injector

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

WHO Supplies Medical Equipment for Post-Marburg...

In a recent move, the World Health Organization has...

Life Sciences Sector Plan Sets UK...

Main Article: UK Life Sciences Sector Plan Sets Sights...

UK Government Launches Ambitious Life Sciences...

Government Unveils Life Sciences Roadmap for Growth and Innovation London,...

Highly Customized Treatments to Offer Specialized...

The Human Medicines Regulations 2025, which came into force...

Janssen Pharmaceutical Companies of Johnson & Johnson has secured approval from the US Food and Drug Administration (FDA) for its Tremfya (guselkumab) One-Press patient-controlled injector for adults with moderate-to-severe plaque psoriasis.

Tremfya is claimed to be the first FDA-approved medication of its kind to provide the One-Press patient-controlled injector.

After starter doses at weeks zero and four, Tremfya is administered as a 100mg subcutaneous injection once every eight weeks.

During the phase 3 multicenter and randomized Orion study, the patient experience with One-Press was evaluated through a validated self-injection assessment questionnaire (SIAQ), which assessed patient experience at weeks zero, four and 12 on a scale of zero (worst) to ten (best) across six domains.

Orian is a phase 3 study designed to assess the pharmacokinetics, efficacy and safety of Tremfya administered with the One-Press injector. The 78 patients have been randomized to receive either Tremfya or placebo.

According to the company, major proportion of patients in the Tremfya group achieved an IGA score of zero or one or a PASI 90 response at week 16 than in the placebo group in the study, said Janssen.

One-Press design enables patients to control the rate and pressure of their injection. A soft click indicates when administration is complete, resulting around 99% of patients reporting a successful first injection.

One-Press is also comprised of a safety system, which protects the needle after use. Patients still reported supportive outcomes with the usability of the One-Press device, after three injections.

Developed by Janssen, Tremfya is a human monoclonal antibody that selectively inhibits the protein interleukin (IL)-23. It is approved in the US, Canada, European Union, Japan and multiple other countries to treat adult patients with moderate-to-severe plaque psoriasis.

Janssen Research & Development immunology development head Dr Newman Yeilding said: “Patients living with plaque psoriasis often struggle with a conventional syringe when administering treatment.

“With the approval of One-Press, patients now have the option to self-administer TREMFYA with a novel device that is both simple and intuitive to use.”

Latest stories

Related stories

WHO Supplies Medical Equipment for Post-Marburg Virus Heal

In a recent move, the World Health Organization has...

Life Sciences Sector Plan Sets UK on Global Growth Track

Main Article: UK Life Sciences Sector Plan Sets Sights...

UK Government Launches Ambitious Life Sciences Sector Plan

Government Unveils Life Sciences Roadmap for Growth and Innovation London,...

Highly Customized Treatments to Offer Specialized Care to UK

The Human Medicines Regulations 2025, which came into force...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back